Razid-20

Razid-20 Drug Interactions

rabeprazole

Manufacturer:

Saga Lab

Distributor:

KTZ
Full Prescribing Info
Drug Interactions
Rabeprazole Sodium, as is the case with other members of the Proton Pump Inhibitor (PPI) class of compounds, is metabolised through the cytochrome P450 (CYP450) hepatic drug metabolising system. Studies in healthy subjects have shown that Rabeprazole Sodium does not have clinically significant interactions with other drugs metabolised by the CYP450 system, such as Warfarin, Phenytoin, Theophylline or Diazepam.
Rabeprazole Sodium produces a profound and long lasting inhibition of gastric acid secretion. An interaction with compounds whose absorption is pH dependent may occur therefore the potential for such interaction was investigated. Co-administration of rabeprazole Sodium results in a 33% decrease in ketoconazole levels and a 22% increase in trough Digoxin levels in normal subjects. Therefore individual patients may need to be monitored to determine if a dosage adjustment is necessary when such drugs are taken concomitantly with RAZID. In clinical trials, antacids were used concomitantly with the administration of RAZID 20 and, in a specific study designed to define this interaction, no interaction with liquid antacids was observed. There was no clinically relevant interaction with food.
In vitro studies with human liver microsomes indicated that Rabeprazole Sodium is metabolised by isoenzymes of CYP450 (CYP2C19 and CYP3A4). The studies suggest a low interaction potential; however the effect on cyclosporin metabolism is similar to that observed for other proton pump inhibitors.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in